FMEA is one of nine tools listed in ICH Q9(R1). The process around it has five parts: initiate with a defined risk question, assess (identify hazards, analyse, evaluate), control (reduce, then accept), communicate the output, and review when events or new knowledge arrive. A first page with the risk question repairs most thin files.
The 2011 text of EU GMP Annex 11 (clause 6) says that where critical data are entered manually there should be an additional check on their accuracy, by a second operator or by validated electronic means. For a BMS or EMS alarm limit, a permitted range on the field and a confirmation step are the practical answer.
A supplier audit that ends when the report is filed tends to find the same observations next time. For audits of active substance suppliers, EU GMP Chapter 5 says required corrective and preventive actions should be implemented. Classify each observation, agree an action and date with the supplier, verify the evidence, and show open actions on the approved supplier list.
A stored value of 22.4 means nothing without its sensor tag, unit, time stamp, status flag, author and audit trail. The MHRA's 2018 data integrity guidance defines metadata as data that describe the attributes of other data and provide context and meaning. Test that backups, exports and migrations carry them.
ICH Q10 describes two management reviews. Section 3.2.4 covers process performance and product quality over the lifecycle; section 4.1 covers the pharmaceutical quality system itself, its objectives and its performance indicators. Deviations on a line belong in the first, the time taken to close deviations in the second.
A signed printout with an electronic file behind it is a hybrid system. The MHRA guidance (2018) says it should be clearly documented what constitutes the whole data set, with all of it reviewed and retained. Check the procedure, the link from printout to file, the review, and the completeness and retention of both.
21 CFR Part 11 and EU GMP Annex 11 overlap on validation, access control and audit trails but differ in emphasis: Part 11 on electronic signatures, Annex 11 on a risk-based system lifecycle. Fixing the destination market in the design basis means the URS and validation plan for BMS, EMS and SCADA are written once.
Personnel, material, product and waste flows decide much of a facility's cross-contamination risk long before sampling starts. Stepped changing, dedicated material airlocks, forward-only product routes and separate waste exits keep them apart; time segregation is the weakest fallback. Check crossings on the layout before room data sheets freeze.
Environmental monitoring and BMS data that support GMP decisions must meet ALCOA+. In practice that means individual logins, time-synchronized controllers, an audit trail users cannot disable, alarms acknowledged with name and comment, and tested backups, with GMP-critical parameters separated early onto a validated system.
A cleanroom can meet its classification on paper, yet fail GMP expectations if HVAC performance is unstable or poorly aligned with operational reality. Cleanroom performance is often discussed in terms of ISO classes or GMP grades.
In pharmaceutical facility design, if the HVAC system is the "lungs," then the Zoning and Pressure Cascade strategy is the "immune system." It creates invisible but effective barriers that prevent microbial ingress and strictly control…
In today’s pharmaceutical manufacturing environment, operational efficiency is no longer just about maximizing output — it must also align with strict GMP compliance, product quality, and…